Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer.

Civenni G, Bosotti R, Timpanaro A, Vàzquez R, Merulla J, Pandit S, Rossi S, Albino D, Allegrini S, Mitra A, Mapelli SN, Vierling L, Giurdanella M, Marchetti M, Paganoni A, Rinaldi A, Losa M, Mira-Catò E, D'Antuono R, Morone D, Rezai K, D'Ambrosio G, Ouafik L, Mackenzie S, Riveiro ME, Cvitkovic E, Carbone GM, Catapano CV.

Cell Metab. 2019 Aug 6;30(2):303-318.e6. doi: 10.1016/j.cmet.2019.05.004. Epub 2019 May 23.

PMID:
31130467
2.

Comprehensive kinome NGS targeted expression profiling by KING-REX.

Carapezza G, Cusi C, Rizzo E, Raddrizzani L, Di Bella S, Somaschini A, Leone A, Lupi R, Mutarelli M, Nigro V, di Bernardo D, Magni P, Isacchi A, Bosotti R.

BMC Genomics. 2019 Apr 23;20(1):307. doi: 10.1186/s12864-019-5676-3.

3.

Eomesodermin controls a unique differentiation program in human IL-10 and IFN-γ coproducing regulatory T cells.

Gruarin P, Maglie S, De Simone M, Häringer B, Vasco C, Ranzani V, Bosotti R, Noddings JS, Larghi P, Facciotti F, Sarnicola ML, Martinovic M, Crosti M, Moro M, Rossi RL, Bernardo ME, Caprioli F, Locatelli F, Rossetti G, Abrignani S, Pagani M, Geginat J.

Eur J Immunol. 2019 Jan;49(1):96-111. doi: 10.1002/eji.201847722. Epub 2018 Nov 29.

PMID:
30431161
4.

PATRI, a Genomics Data Integration Tool for Biomarker Discovery.

Ukmar G, Melloni GEM, Raddrizzani L, Rossi P, Di Bella S, Pirchio MR, Vescovi M, Leone A, Callari M, Cesarini M, Somaschini A, Della Vedova G, Daidone MG, Pettenella M, Isacchi A, Bosotti R.

Biomed Res Int. 2018 Jun 28;2018:2012078. doi: 10.1155/2018/2012078. eCollection 2018.

5.

Intestinal IFN-γ-producing type 1 regulatory T cells coexpress CCR5 and programmed cell death protein 1 and downregulate IL-10 in the inflamed guts of patients with inflammatory bowel disease.

Alfen JS, Larghi P, Facciotti F, Gagliani N, Bosotti R, Paroni M, Maglie S, Gruarin P, Vasco CM, Ranzani V, Frusteri C, Iseppon A, Moro M, Crosti MC, Gatti S, Pagani M, Caprioli F, Abrignani S, Flavell RA, Geginat J.

J Allergy Clin Immunol. 2018 Nov;142(5):1537-1547.e8. doi: 10.1016/j.jaci.2017.12.984. Epub 2018 Jan 31.

6.

Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.

Magnaghi P, Salom B, Cozzi L, Amboldi N, Ballinari D, Tamborini E, Gasparri F, Montagnoli A, Raddrizzani L, Somaschini A, Bosotti R, Orrenius C, Bozzi F, Pilotti S, Galvani A, Sommer J, Stacchiotti S, Isacchi A.

Mol Cancer Ther. 2018 Mar;17(3):603-613. doi: 10.1158/1535-7163.MCT-17-0324. Epub 2017 Dec 13.

7.

Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.

Milione M, Ardini E, Christiansen J, Valtorta E, Veronese S, Bosotti R, Pellegrinelli A, Testi A, Pietrantonio F, Fucà G, Wei G, Murphy D, Siena S, Isacchi A, De Braud F.

Oncotarget. 2017 Jul 24;8(33):55353-55360. doi: 10.18632/oncotarget.19512. eCollection 2017 Aug 15.

8.

Establishment and genomic characterization of the new chordoma cell line Chor-IN-1.

Bosotti R, Magnaghi P, Di Bella S, Cozzi L, Cusi C, Bozzi F, Beltrami N, Carapezza G, Ballinari D, Amboldi N, Lupi R, Somaschini A, Raddrizzani L, Salom B, Galvani A, Stacchiotti S, Tamborini E, Isacchi A.

Sci Rep. 2017 Aug 23;7(1):9226. doi: 10.1038/s41598-017-10044-3.

9.

KAOS: a new automated computational method for the identification of overexpressed genes.

Nuzzo A, Carapezza G, Di Bella S, Pulvirenti A, Isacchi A, Bosotti R.

BMC Bioinformatics. 2016 Nov 8;17(Suppl 12):340. doi: 10.1186/s12859-016-1188-1.

10.

Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.

Carrella D, Manni I, Tumaini B, Dattilo R, Papaccio F, Mutarelli M, Sirci F, Amoreo CA, Mottolese M, Iezzi M, Ciolli L, Aria V, Bosotti R, Isacchi A, Loreni F, Bardelli A, Avvedimento VE, di Bernardo D, Cardone L.

Oncotarget. 2016 Sep 13;7(37):58743-58758. doi: 10.18632/oncotarget.11318.

11.

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.

Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A.

Mol Cancer Ther. 2016 Apr;15(4):628-39. doi: 10.1158/1535-7163.MCT-15-0758. Epub 2016 Mar 3.

12.

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.

Amatu A, Somaschini A, Cerea G, Bosotti R, Valtorta E, Buonandi P, Marrapese G, Veronese S, Luo D, Hornby Z, Multani P, Murphy D, Shoemaker R, Lauricella C, Giannetta L, Maiolani M, Vanzulli A, Ardini E, Galvani A, Isacchi A, Sartore-Bianchi A, Siena S.

Br J Cancer. 2015 Dec 22;113(12):1730-4. doi: 10.1038/bjc.2015.401. Epub 2015 Dec 3.

13.

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.

Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, Somaschini A, Raddrizzani L, Palmeri L, Banfi P, Bonazzina E, Misale S, Marrapese G, Leone A, Alzani R, Luo D, Hornby Z, Lim J, Veronese S, Vanzulli A, Bardelli A, Martignoni M, Davite C, Galvani A, Isacchi A, Siena S.

J Natl Cancer Inst. 2015 Nov 12;108(1). pii: djv306. doi: 10.1093/jnci/djv306. Print 2016 Jan.

14.

Preface: BITS2014, the annual meeting of the Italian Society of Bioinformatics.

Facchiano A, Angelini C, Bosotti R, Guffanti A, Marabotti A, Marangoni R, Pascarella S, Romano P, Zanzoni A, Helmer-Citterich M.

BMC Bioinformatics. 2015;16 Suppl 9:S1. doi: 10.1186/1471-2105-16-S9-S1. Epub 2015 Jun 1.

15.

The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.

Ardini E, Bosotti R, Borgia AL, De Ponti C, Somaschini A, Cammarota R, Amboldi N, Raddrizzani L, Milani A, Magnaghi P, Ballinari D, Casero D, Gasparri F, Banfi P, Avanzi N, Saccardo MB, Alzani R, Bandiera T, Felder E, Donati D, Pesenti E, Sartore-Bianchi A, Gambacorta M, Pierotti MA, Siena S, Veronese S, Galvani A, Isacchi A.

Mol Oncol. 2014 Dec;8(8):1495-507. doi: 10.1016/j.molonc.2014.06.001. Epub 2014 Jun 12.

16.

Cell line identity finding by fingerprinting, an optimized resource for short tandem repeat profile authentication.

Somaschini A, Amboldi N, Nuzzo A, Scacheri E, Ukmar G, Ballinari D, Malyszko J, Raddrizzani L, Landonio A, Gasparri F, Galvani A, Isacchi A, Bosotti R.

Genet Test Mol Biomarkers. 2013 Mar;17(3):254-9. doi: 10.1089/gtmb.2012.0359. Epub 2013 Jan 28.

PMID:
23356232
17.

Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells.

Bosotti R, Carpinelli P, Healy S, Locatelli G, Cappella P, Lanfrancone L, Calogero R, Moll J, Isacchi A.

Gene. 2012 Feb 25;494(2):202-8. doi: 10.1016/j.gene.2011.08.014. Epub 2011 Sep 2.

PMID:
21914463
18.

Identification of candidate substrates for poly(ADP-ribose) polymerase-2 (PARP2) in the absence of DNA damage using high-density protein microarrays.

Troiani S, Lupi R, Perego R, Depaolini SR, Thieffine S, Bosotti R, Rusconi L.

FEBS J. 2011 Oct;278(19):3676-87. doi: 10.1111/j.1742-4658.2011.08286.x. Epub 2011 Sep 6.

19.

Summarizing probe intensities of affymetrix GeneChip 3' expression arrays taking into account day-to-day variability.

Magni P, Simeone A, Healy S, Isacchi A, Bosotti R.

IEEE/ACM Trans Comput Biol Bioinform. 2011 Sep-Oct;8(5):1425-30. doi: 10.1109/TCBB.2010.82.

PMID:
21778528
20.

Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.

Balabanov S, Gontarewicz A, Keller G, Raddrizzani L, Braig M, Bosotti R, Moll J, Jost E, Barett C, Rohe I, Bokemeyer C, Holyoake TL, Brümmendorf TH.

PLoS One. 2011 Apr 26;6(4):e19164. doi: 10.1371/journal.pone.0019164.

21.

Discovery of drug mode of action and drug repositioning from transcriptional responses.

Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R, Murino L, Tagliaferri R, Brunetti-Pierri N, Isacchi A, di Bernardo D.

Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14621-6. doi: 10.1073/pnas.1000138107. Epub 2010 Aug 2.

22.

Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study.

Locatelli G, Bosotti R, Ciomei M, Brasca MG, Calogero R, Mercurio C, Fiorentini F, Bertolotti M, Scacheri E, Scaburri A, Galvani A, Pesenti E, De Baere T, Soria JC, Lazar V, Isacchi A.

Mol Cancer Ther. 2010 May;9(5):1265-73. doi: 10.1158/1535-7163.MCT-09-1163. Epub 2010 Apr 27.

23.

Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships.

Vanotti E, Amici R, Bargiotti A, Berthelsen J, Bosotti R, Ciavolella A, Cirla A, Cristiani C, D'Alessio R, Forte B, Isacchi A, Martina K, Menichincheri M, Molinari A, Montagnoli A, Orsini P, Pillan A, Roletto F, Scolaro A, Tibolla M, Valsasina B, Varasi M, Volpi D, Santocanale C.

J Med Chem. 2008 Feb 14;51(3):487-501. doi: 10.1021/jm700956r. Epub 2008 Jan 18.

PMID:
18201066
24.

Cross platform microarray analysis for robust identification of differentially expressed genes.

Bosotti R, Locatelli G, Healy S, Scacheri E, Sartori L, Mercurio C, Calogero R, Isacchi A.

BMC Bioinformatics. 2007 Mar 8;8 Suppl 1:S5.

25.

PoInTree: a polar and interactive phylogenetic tree.

Carreras M, Gianti E, Sartori L, Plyte SE, Isacchi A, Bosotti R.

Genomics Proteomics Bioinformatics. 2005 Feb;3(1):58-60. Erratum in: Genomics Proteomics Bioinformatics. 2005 May;3(2):128. Marco, Cerreras [corrected to Cerreras, Marco]; Eleonora, Gianti [corrected to Gianti, Eleonora]; Luca, Sartori [corrected to Sartori, Luca]; Edward, Plyte Simon [corrected to Plyte, Simon Edward]; Antonella, Isacchi [corrected to Isacchi, Antonella]; Robe.

26.

Sequence and structural analysis of kinase ATP pocket residues.

Vulpetti A, Bosotti R.

Farmaco. 2004 Oct;59(10):759-65.

PMID:
15474052
27.

Drf1, a novel regulatory subunit for human Cdc7 kinase.

Montagnoli A, Bosotti R, Villa F, Rialland M, Brotherton D, Mercurio C, Berthelsen J, Santocanale C.

EMBO J. 2002 Jun 17;21(12):3171-81.

28.

Detection of a polymorphism in exon 8 of the human CD86 gene.

Delneste Y, Bosotti R, Magistrelli G, Bonnefoy JY, Gauchat JF.

Immunogenetics. 2000 Jul;51(8-9):762-3. No abstract available.

PMID:
10941851
29.

FAT: a novel domain in PIK-related kinases.

Bosotti R, Isacchi A, Sonnhammer EL.

Trends Biochem Sci. 2000 May;25(5):225-7. No abstract available.

PMID:
10782091
30.

Activation of Zap-70 tyrosine kinase due to a structural rearrangement induced by tyrosine phosphorylation and/or ITAM binding.

Visco C, Magistrelli G, Bosotti R, Perego R, Rusconi L, Toma S, Zamai M, Acuto O, Isacchi A.

Biochemistry. 2000 Mar 14;39(10):2784-91.

PMID:
10704231
31.

Role of the Src homology 2 domains and interdomain regions in ZAP-70 phosphorylation and enzymatic activity.

Magistrelli G, Bosotti R, Valsasina B, Visco C, Perego R, Toma S, Acuto O, Isacchi A.

Eur J Biochem. 1999 Dec;266(3):1166-73.

Supplemental Content

Loading ...
Support Center